Inventor · disambiguated record
William H. Rastetter
Also filed as: RASTETTER WILLIAM H
17 granted patents·6 pending applications·2,054 citations·filing 1984–2005
97Inventor score
Top patents by PatentIndex Score
23 records- 0199US7422739B2Anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Sep 9, 2008·166 cites·13 claims
- 0298US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0398US5843439ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaFiled 1995·Granted Dec 1, 1998·336 cites·7 claims
- 0498US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0597US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 0696US7381560B2Expression and use of anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Jun 3, 2008·45 cites·10 claims
- 0793US7744877B2Expression and use of anti-CD20 AntibodiesBIOGEN IDEC INC·Filed 2002·Granted Jun 29, 2010·38 cites·8 claims
- 0893US6733763B2Induction of cytotoxic T-lymphocyte responsesBIOGEN IDEC INC·Filed 2000·Granted May 11, 2004·39 cites·19 claims
- 0992US4757012AAscorbic acid intermediates and process enzymesGENENTECH INC·Filed 1984·Granted Jul 12, 1988·48 cites·5 claims
- 1090US5585103AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1992·Granted Dec 17, 1996·97 cites·20 claims
- 1189US5008193AAscorbic acid intermediates and process enzymesGENENTECH INC·Filed 1987·Granted Apr 16, 1991·43 cites·12 claims
- 1288US5004690AAscorbic acid intermediates and process enzymesGENENTECH INC·Filed 1989·Granted Apr 2, 1991·37 cites·1 claims
- 1388US4758514AAscorbic acid intermediates and process enzymesGENENTECH INC·Filed 1984·Granted Jul 19, 1988·35 cites·14 claims
- 1487US5695770AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Dec 9, 1997·74 cites·9 claims
- 1586US5709860AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1994·Granted Jan 20, 1998·73 cites·23 claims
- 1684US6270769B1Induction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Aug 7, 2001·61 cites·35 claims
- 1764US2006057162A1Induction of cytotoxic T-lymphocyte responsesBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 1860US2005186205A1Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell LymphomaFiled 2004·Application pending·0 cites
- 1960US2003021781A1Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 2049US2004197331A1Induction of cytotoxic T-lymphocyte responsesBIOGEN IDEC INC·Filed 2003·Application pending·0 cites
- 2148US2003082172A1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMACEUTICALS·Filed 2002·Application pending·0 cites
- 2239US2003012781A1Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereofFiled 2001·Application pending·0 cites
- 2338US6197311B1Induction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1998·Granted Mar 6, 2001·5 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when William H. Rastetter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →